CTRI/2014/08/004857已完成1 期
AN OPEN-LABEL, SINGLE-TREATMENT, SINGLE-PERIOD, SINGLE DOSE, CLINICAL PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF INACTIVATED TETRAVALENT INFLUENZA VACCINE (SPLIT VIRION) OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS. - NA
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male subjects aged between 18 and 45 years (both inclusive).
- •-Subjectsâ?? weight within ±15% of the ideal height-weight chart of Life Insurance Corporation of India for non-medical cases.
- •Ability to communicate effectively with study personnel.
- •-Willingness to adhere to the protocol requirements.
- •-Be able to give consent for participation in the trial.
- •-Normal health as determined by personal medical history, clinical examination, and laboratory examinations data during screening (within the clinically acceptable range).
排除标准
- •- History of anaphylaxis or serious reactions to vaccines, egg proteins, gelatin or gelatin containing product.
- •- Subjects who are taking immunostimulant therapy (e.g. interferons) or immunosuppressant medications (e.g. corticosteroids, cytotoxic drugs or antimetabolites, etc.).
- •- Subjects who are known to be suffering from diseases which can affect immune competence e.g. diabetes, immunodeficiency disorders or known to be HIV positive.
- •-Subjects who have received immunoglobulins parenterally during the preceding 3 months.
- •Subjects who have received any vaccine in the preceding 6 months.
- •- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement.
- •-History or presence of significant alcoholism or drug abuse within the past one-year.
- •-History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco product.
- •-Difficulty with donating blood.
- •-Blood pressure less than 100/60 (Systolic/diastolic) mm Hg or more than 140/90 (Systolic/diastolic) mm Hg.
- •-Pulse less than 60/minute or more than 110/minute.
- •-Any ECG abnormalities.
- •-Any clinically significant abnormal laboratory values during screening.
- •-Any clinically significant chest X-Ray findings during screening.
- •-Major illness during 3 months before the screening period.
- •-Subjects who have participated in drug research studies within past 3 months.
- •-Subjects who have donated one unit (350ml) of blood in the past 3 months.
- •Also subjects will be assessed for alcohol and drug of abuse consumption at the time of check in during the study. Subjects who are found positive in alcohol breathe test and urine test for drug of abuse, will not be enrolled in the study.
研究者
相似试验
进行中（未招募）
1 期
A CLINICAL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF INACTIVATED HEPATITIS A VACCINE (ADSORBED) I.P. OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT HUMAN SUBJECTSCTRI/2020/01/022797Cadila Healthcare Ltd
已完成
1 期
TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE MEASLES AND RUBELLA VACCINE IN HEALTHY, ADULT, MALE, HUMAN SUBJECTSCTRI/2012/08/002874Cadila Healthcare Limited24
已完成
1 期
TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE MEASLES, MUMPS AND RUBELLA VACCINE IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS UNDER FASTING CONDITIONS.CTRI/2012/08/002875Cadila Healthcare Limited24
已完成
1 期
Phase 1 clinical study to assess the safety and tolerability of Haemophilus inf type B conjugate vaccineCTRI/2014/01/004340Cadila Healthcare Ltd24
已完成
1 期
TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE MEASLES AND RUBELLA VACCINE INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS UNDER FASTING CONDITIONS.CTRI/2012/07/002841Cadila Healthcare Limited24